{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:37:48Z","timestamp":1779291468821,"version":"3.51.4"},"reference-count":15,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T00:00:00Z","timestamp":1471305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Chronic hepatitis C is a major cause of chronic liver disease, including liver cirrhosis and hepatocellular carcinoma. The development of direct-acting antivirals (DAAs) revolutionized hepatitis C virus (HCV) treatment by offering genuine prospects for the first comprehensive cure of a chronic viral infection in humans. While antiviral resistance is a significant limitation for interferon-based therapies, resistance and treatment failure still appear to be present in a small fraction of patients even in state-of-the-art DAA combination therapies. Therefore, treatment failure and resistance still remain a clinical challenge for the management of patients not responding to DAAs. In this special issue of Viruses on HCV drug resistance, mechanisms of antiviral resistance for different classes of antiviral drugs are described. Furthermore, the detection and monitoring of resistance in clinical practice, the clinical impact of resistance in different patient groups and strategies to prevent and address resistance and treatment failure using complementary antiviral strategies are reviewed.<\/jats:p>","DOI":"10.3390\/v8080226","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T10:03:21Z","timestamp":1471341801000},"page":"226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure"],"prefix":"10.3390","volume":"8","author":[{"given":"Che","family":"Colpitts","sequence":"first","affiliation":[{"name":"Institut de Recherche sur les Maladies Virales et H\u00e9patiques, Inserm, U1110, 3 rue Koeberl\u00e9, 67000 Strasbourg, France"},{"name":"Universit\u00e9 de Strasbourg, 67000 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Baumert","sequence":"additional","affiliation":[{"name":"Institut de Recherche sur les Maladies Virales et H\u00e9patiques, Inserm, U1110, 3 rue Koeberl\u00e9, 67000 Strasbourg, France"},{"name":"Universit\u00e9 de Strasbourg, 67000 Strasbourg, France"},{"name":"Institut Hospitalo-Universitaire, P\u00f4le H\u00e9pato-Digestif, Hopitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2014The arc of a medical triumph","volume":"370","author":"Chung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3390\/v7122968","article-title":"Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals","volume":"7","author":"Ahmed","year":"2015","journal-title":"Viruses"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/v7102868","article-title":"Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance","volume":"7","author":"Eltahla","year":"2015","journal-title":"Viruses"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/v7112902","article-title":"Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications","volume":"7","author":"Perales","year":"2015","journal-title":"Viruses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.3390\/v7102876","article-title":"HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy","volume":"7","author":"Chayama","year":"2015","journal-title":"Viruses"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.3390\/v7122941","article-title":"Virologic Tools for HCV Drug Resistance Testing","volume":"7","author":"Fourati","year":"2015","journal-title":"Viruses"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(16)00120-1","article-title":"New perspectives for preventing hepatitis C virus liver graft infection","volume":"16","author":"Felmlee","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.3390\/v7092864","article-title":"Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance","volume":"7","author":"Roche","year":"2015","journal-title":"Viruses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.3390\/v7112898","article-title":"Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection","volume":"7","author":"Zeisel","year":"2015","journal-title":"Viruses"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.3390\/v7122933","article-title":"Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection","volume":"7","author":"Lovelace","year":"2015","journal-title":"Viruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/v8060176","article-title":"Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance","volume":"8","author":"Mesalam","year":"2016","journal-title":"Viruses"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/8\/226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:28:30Z","timestamp":1760210910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/8\/226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,16]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"alternative-id":["v8080226"],"URL":"https:\/\/doi.org\/10.3390\/v8080226","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,16]]}}}